Malignant lymphoma and malignant angioendotheliomatosis: One disease

Bhawan, Jag; Wolff, Sheldon M.; Ucci, Angelo A.; Bhan, Atul K.

doi:10.1002/1097-0142(19850201)55:3<570::aid-cncr2820550316>3.0.co;2-0

Cited by 136 publications

(68 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This entity was initially considered as an endothelial neoplasm, but with the advent of immunohistochemical studies, the lymphoid origin of this peculiar disease was established, imposing its reclassification as angioendotheliotropic lymphoma (Kiel), angiotropic large cell lymphoma (LukesCollins), and unclassified large B-cell lymphoma in the Revised European American Lymphoma (REAL) Classification [1][2][3].…”

Section: Introductionmentioning

confidence: 99%

Disseminated Intravascular B-Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracycline-Based Immunochemotherapy

Bouzani¹,

Karmiris²,

Rontogianni

et al. 2006

The Oncologist

View full text Add to dashboard Cite

The purpose of this study was to evaluate the use of combination anthracycline-based immunochemotherapy in intravascular lymphoma (IVL). This is an extremely rare, disseminated, and aggressive extranodal CD20 + non-Hodgkin's lymphoma (NHL) with poor outcome following anthracycline-based chemotherapy. From a population of 700 newly diagnosed patients with NHL who were registered and followed up at our unit between 1990 and 2005, three cases (0.4%) have been classified as IVL. Among the patients, there were two men and one woman, with a median age of 52 years. We have assessed the clinicopathological characteristics, response to therapy, and outcome. All patients presented with systemic symptoms and disseminated disease. All patients received anthracycline-based chemotherapy in combination with the anti-CD20 monoclonal antibody rituximab (immunochemotherapy). Complete remission was achieved in all three patients, and currently all remain progression free with a follow-up of 24-45 months. In conclusion, anthracycline-based immunochemotherapy induces durable remissions in patients with IVL, an ultimately fatal disease, suggesting that the clinical course of this disease may be altered with immunochemotherapy. The Oncologist 2006;11:923-928

show abstract

Section: Introductionmentioning

confidence: 99%

Disseminated Intravascular B-Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracycline-Based Immunochemotherapy

Bouzani¹,

Karmiris²,

Rontogianni

et al. 2006

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Initially, this neoplasm had been believed to originate from the vascular endothelial cells because of its unique intravascular proliferative pattern [2,3]. In 1985, however, it was proved to derive from the B lymphocytes using immunohistochemical staining [4,5].…”

Section: Introductionmentioning

confidence: 99%

CD5+ Epstein-Barr virus-positive intravascular large B-cell lymphoma in the uterus co-existing with huge myoma

et al. 2005

View full text Add to dashboard Cite

A 42-year-old female underwent hysterectomy because of a huge uterine mass. Histologically, she was diagnosed as having intravascular lymphoma co-existing with myoma uteri. Lymphoma cells were large in size and were positive for CD5, CD20, CD45, CD79a, lambda light chain, and EBV but were negative for CD3 and cyclin D1. No other organs except for the adjoining bilateral ovaries seemed to be affected by the lymphoma cells. She received the combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisolone) together with rituximab and has been well without definite disease progression. So far, this is the first case of CD5 + EBV + intravascular large B-cell lymphoma (CD5 + EBV + IVLBL) in the uterus of a patient who was incidentally diagnosed and successfully treated. Am.

show abstract

“…Ansell et al (5)suggested a lymphoid origin in 1982 by demonstrating surface Ig on the neoplastic cells. Subsequently, Bhawan et al (6) and Wrotnowski et al (7) reported leukocyte common antigen expression in 1985. The lymphoid nature was confirmed by Wick et al (8) in 1986.…”

mentioning

confidence: 99%

Angiotropic Lymphoma: An Immunophenotypically and Clinically Heterogeneous Lymphoma

Coupland²,

et al. 2001

View full text Add to dashboard Cite

Angiotropic lymphoma (AL) is an uncommon lymphoma often presenting with nonspecific clinical features and having a high mortality rate. Although not specifically recognized by the Revised European-American Classification of Lymphoid Neoplasms, it likely will appear as a subtype of diffuse large B-cell lymphoma in the upcoming WHO classification. Some authors may also consider it to be a subtype of cutaneous lymphomas. Recent studies have reported an immunophenotypic heterogeneity of AL, and in rare instances, an association with other NHL. To further characterize AL, we studied the immunophenotype by immunohistochemistry for CD5, CD10, CD20, bcl-2, and bcl-6 in 18 cases of B-cell AL identified at three medical centers in North America. Bcl-2 gene rearrangement status by polymerase chain reaction and Epstein Barr virus status by in situ hybridization also were evaluated.Eight men and 10 women were identified with AL (median age 71 years). Eleven patients were diagnosed in life and seven were diagnosed at autopsy. Neurologic symptoms were the most common presentation, seen in six patients. Skin was the most commonly biopsied site. All showed classic intravascular localization; in two cases, there was also a minor diffuse large cell lymphoma component observed in some organs. Most (89%) of the cases expressed bcl-2 protein; CD10, bcl-6 and CD5 were each expressed in 22% of cases. Based on CD5 and CD10 expression, three major groups were evident: CD5؊, CD10؊ (11 cases); CD5؉, CD10؊ (3 cases), and CD5؊, CD10؉ (3 cases). Even though a follicle center lymphoma preceded the AL in one patient, we did not detect bcl-2 gene rearrangement in any of these cases. All cases were negative for Epstein Barr virus. Of the five treated with chemotherapy, two achieved a complete remission.Based on these findings, we conclude that ALs are clinically and immunophenotypically heterogeneous and may represent more than one pathogenetic entity. In some instances AL may be preceded by another lymphoproliferative disorder, raising the possibility that some cases of AL may represent a transformation from another type of lymphoma. Cutaneous manifestations of AL are common; however, it appears to be a systemic lymphoma. Although often fatal, patients with AL who are diagnosed early and treated with chemotherapy may achieve remission.

show abstract

Malignant lymphoma and malignant angioendotheliomatosis: One disease

Cited by 136 publications

References 20 publications

Disseminated Intravascular B-Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracycline-Based Immunochemotherapy

Disseminated Intravascular B-Cell Lymphoma: Clinicopathological Features and Outcome of Three Cases Treated with Anthracycline-Based Immunochemotherapy

CD5+ Epstein-Barr virus-positive intravascular large B-cell lymphoma in the uterus co-existing with huge myoma

Angiotropic Lymphoma: An Immunophenotypically and Clinically Heterogeneous Lymphoma

Contact Info

Product

Resources

About